Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

K.B. Kim; R. Kefford; A.C. Pavlick; J.R. Infante; A. Ribas; J.A. Sosman; L.A. Fecher; Michael Millward; G.A. Mcarthur; P. Hwu; R. Gonzalez; P.A. Ott; G.V. Long; O.S. Gardner; D. Ouellet; Y. Xu; D.J. Demarini; N.T. Le; K. Patel; K.D. Lewis

doi:10.1200/JCO.2012.43.5966

Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

K.B. Kim, R. Kefford, A.C. Pavlick, J.R. Infante, A. Ribas, J.A. Sosman, L.A. Fecher, Michael Millward, G.A. Mcarthur, P. Hwu, R. Gonzalez, P.A. Ott, G.V. Long, O.S. Gardner, D. Ouellet, Y. Xu, D.J. Demarini, N.T. Le, K. Patel, K.D. Lewis

Research output: Contribution to journal › Article › peer-review

410 Citations (Scopus)

Original language	English
Pages (from-to)	482-489
Journal	Journal of Clinical Oncology
Volume	31
Issue number	4
DOIs	https://doi.org/10.1200/JCO.2012.43.5966
Publication status	Published - 2013

Access to Document

10.1200/JCO.2012.43.5966

Cite this

Kim, K. B., Kefford, R., Pavlick, A. C., Infante, J. R., Ribas, A., Sosman, J. A., Fecher, L. A., Millward, M., Mcarthur, G. A., Hwu, P., Gonzalez, R., Ott, P. A., Long, G. V., Gardner, O. S., Ouellet, D., Xu, Y., Demarini, D. J., Le, N. T., Patel, K., & Lewis, K. D. (2013). Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. Journal of Clinical Oncology, 31(4), 482-489. https://doi.org/10.1200/JCO.2012.43.5966

@article{d6a983cace5f45979cdcc15959a73245,

title = "Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor",

author = "K.B. Kim and R. Kefford and A.C. Pavlick and J.R. Infante and A. Ribas and J.A. Sosman and L.A. Fecher and Michael Millward and G.A. Mcarthur and P. Hwu and R. Gonzalez and P.A. Ott and G.V. Long and O.S. Gardner and D. Ouellet and Y. Xu and D.J. Demarini and N.T. Le and K. Patel and K.D. Lewis",

year = "2013",

doi = "10.1200/JCO.2012.43.5966",

language = "English",

volume = "31",

pages = "482--489",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "4",

}

Kim, KB, Kefford, R, Pavlick, AC, Infante, JR, Ribas, A, Sosman, JA, Fecher, LA, Millward, M, Mcarthur, GA, Hwu, P, Gonzalez, R, Ott, PA, Long, GV, Gardner, OS, Ouellet, D, Xu, Y, Demarini, DJ, Le, NT, Patel, K & Lewis, KD 2013, 'Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor', Journal of Clinical Oncology, vol. 31, no. 4, pp. 482-489. https://doi.org/10.1200/JCO.2012.43.5966

TY - JOUR

T1 - Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

AU - Kim, K.B.

AU - Kefford, R.

AU - Pavlick, A.C.

AU - Infante, J.R.

AU - Ribas, A.

AU - Sosman, J.A.

AU - Fecher, L.A.

AU - Millward, Michael

AU - Mcarthur, G.A.

AU - Hwu, P.

AU - Gonzalez, R.

AU - Ott, P.A.

AU - Long, G.V.

AU - Gardner, O.S.

AU - Ouellet, D.

AU - Xu, Y.

AU - Demarini, D.J.

AU - Le, N.T.

AU - Patel, K.

AU - Lewis, K.D.

PY - 2013

Y1 - 2013

U2 - 10.1200/JCO.2012.43.5966

DO - 10.1200/JCO.2012.43.5966

M3 - Article

C2 - 23248257

SN - 0732-183X

VL - 31

SP - 482

EP - 489

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 4

ER -